R

Revance Therapeutics
D

RVNC

4.01000
USD
0.21
(5.53%)
Market Closed
Volume
91,696
EPS
-2
Div Yield
-
P/E
-1
Market Cap
420,658,576
Related Instruments
    B
    BHC
    -0.27000
    (-3.08%)
    8.48500 USD
    H
    HRTX
    -0.04500
    (-3.61%)
    1.20000 USD
    I
    IRWD
    0.10500
    (2.56%)
    4.20500 USD
    T
    TEVA
    -0.315
    (-1.88%)
    16.440 USD
    More
News

Title: Revance Therapeutics

Sector: Healthcare
Industry: Biotechnology
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.